Considerable Opportunity Remains for an Antiplatelet Therapy that, Combined with Aspirin, Causes Less Bleeding than the Combination of Plavix/Iscover and Aspirin, According to a New Report from Decision Resources WALTHAM, Mass., May 15
WALTHAM, Mass., May 15 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that Daiichi Sankyo/Eli Lilly's Effient offers improvement in
patient compared to Sanofi-Aventis/Bristol Myers Squibb's Plavix/Iscover in
the treatment of post-myocardial infarction. Effient and AstraZeneca's
ticagrelor, which is in Phase III trials, are positioned to offer advantages
over Plavix/Iscover such as quick onset of action, greater potency, consistent
effect, and a quick offset of action. However, clinical trials demonstrate
that Effient cause more major bleeding than Plavix/Iscover and that ticagrelor
must be twice-daily dosed, in comparison with Plavix/Iscover's once-daily
dose. The new ADP receptor antagonists Effient and ticagrelor will be launched
in 2009 and 2011, respectively. However, with Plavix/Iscover's patent expiry
in 2011, only modest patient shares are expected for the new agents because of
the increased competitiveness of generic clopidogrel.
The new report entitled Post-Myocardial Infarction: Emerging Therapies
Must Offer Physicians More Evidence to Prove Clear Benefits further finds that
an unmet need exists for an antiplatelet therapy for post-myocardial
infarction that is as effective as Plavix/Iscover but that, combined with
aspirin, causes less major bleeding than the combination of Plavix/Iscover and
aspirin. An agent of this type would earn 43 percent patient share in
post-myocardial infarction, according to primary care physicians.
"Surveyed primary care physicians consider less bleeding an important
safety attribute, and the results of our survey indicate that they are not
satisfied with the level of bleeding caused by the combination of
Plavix/Iscover and aspirin," said Jeremy Goldman, M.D., analyst at Decision
Resources. "Because Plavix/Iscover is the only adenosine diphosphate receptor
antagonist used in combination with aspirin (excluding the occasional use of
ticlopidine [Roche/Sanofi-Aventis's Ticlid, Daiichi Sankyo's Panaldine,
generics]) in the United States, there is considerable opportunity for an
antiplatelet agent that is as effective as Plavix/Iscover when it is added to
aspirin but does not bring the higher risk of major bleeding."
About the Report
Post-Myocardial Infarction: Emerging Therapies Must Offer Physicians More
Evidence to Prove Clear Benefits is a DecisionBase 2008 report from Decision
Resources. DecisionBase 2008 combines market forecasts with clinical and
commercial end points to assess market share projections in 35 indications.
These outputs are driven by quantitative and qualitative primary research.
DecisionBase 2008 provides detailed market share, patient share, and
price-per-day projections for emerging drugs in development. The market share
projections are based on prescriber surveys that compare physicians'
expectations of a potential target product profile with an emerging product
profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of
the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com), is a world
leader in market research publications, advisory services, and consulting
designed to help clients shape strategy, allocate resources, and master their
chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources
781-296-2563
emarshall@dresources.com
SOURCE Decision Resources
